June 2016

Feature

From the Field

A Method of Deriving Estimates of Health State Utilities for Patients With Metastatic Breast Cancer

06/20/2016

Gabriel Tremblay , DBA, MSc;

Stacie Hudgens , MA, MSc;

Andrew Briggs , DPhil, MSc;

Andrew J. Lloyd , DPhil;

Anna Forsythe , PharmD, MBA, MSc;

Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...

...

06/20/2016

Journal of Clinical Pathways

Research Reports

SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors

06/20/2016

Brooke Hoverman ;

Stephanie Trenkner , BS;

Carlena Magley , BS;

Hilary Biddle , RN, BSN, CCRC;

Nancy Ehmke , RN, MN, AOCN;

Breck Hunnicutt , RN, BSN, CCRC;

Christina Zelt , RN, MSN;

Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...

...

06/20/2016

Journal of Clinical Pathways

Column

Pharma Insights

Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

06/20/2016

Rick Lifsitz , MBA;

Larry Blandford , PharmD;

The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...

The...

06/20/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Beyond Medication Class: How Specific Should the Clinical Pathway Get?

06/20/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Taha Khan , PharmD, RPh;

Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...

...

06/20/2016

Journal of Clinical Pathways

Insights

Interview

The Potentials and Barriers of Precision Medicine in Oncology

06/20/2016

In the mid-1980s, cancer researchers shifted their focus from determining the location of a cancer to identifying the genetic mutations that create it.1 This shift gave birth to a new field of study known as...

In the...

06/20/2016

Journal of Clinical Pathways

Interview

Reducing Waste in Oncology Drug Use

06/20/2016

  According to a recent report, prescription drug costs rose by more than 12% in 2014 and are expected to continue to rise by more than 7% through 2018.1 In addition, a study of the out-of-pocket costs...

...

06/20/2016

Journal of Clinical Pathways

News

Conference Coverage

Perceptions of ICER Reports and Health Technology Assessments in the United States

06/20/2016

JCP Editors

Michael Barry, MD, PhD, clinical director at the National Centre for Pharmaceoeconomics in Dublin, Ireland, initiated the session, “Payers’ use of Independent Reports in Decision Making—Will There Be an ICER Effect,”...

...

06/20/2016

Journal of Clinical Pathways

Conference Coverage

2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting

06/20/2016

JCP Editors

Founded in 1995, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is one of the leading organizations promoting the research of health economics and value-based care. Currently, ISPOR is...

...

06/20/2016

Journal of Clinical Pathways

Department

Research in Review

Bundled Payments Model Utilizing Clinical Pathways a Success for Hip and Knee Replacements

06/20/2016

JCP Editors

A Bundled Payments for Care Improvement model developed at New York University Langone Medical Center (NYULMC), New York City, NY, was successful at improving institutional efficiency and providing more value...

...

06/20/2016

Journal of Clinical Pathways

Research in Review

Rectal Cancer Treatment Utilizing Chemotherapy and Radiation Therapy Improving Over Time

06/20/2016

JCP Editors

A review of the last decade of care for rectal cancer has found evidence of significant progress in improving patient outcomes despite a number of challenges. For their review, researchers led by Nader N...

...

06/20/2016

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

June 2016

Feature

Column

Insights

News

Department

Current Issue

Special Reports

Subscribe

June 2016 Volume 2

Specialties

Events

Year Round Education

HMP Global Products